Johnson & Johnson (JNJ) said Monday that its potential ulcerative colitis treatment icotrokinra met the primary endpoint of clinical response in all dosages in a 252-patient phase 2b study.
The investigational drug also showed "clinically meaningful" differences versus placebo in secondary endpoints of clinical remission, symptomatic remission, and endoscopic improvement at week 12, the company said.
Icotrokinra at the highest doses showed a response rate of 63.5% for patients with chronic large intestine disease after 12 weeks, versus 27% for placebo, and a remission rate of 30.2%, versus 11.1% for the placebo, the company said.
It added that remission and response rates continued to improve through week 28.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.